Fat-embolism syndrome (respiratory insufficiency syndrome). A rationale for treatment.
D000293:Adolescent; D000328:Adult; D000438:Alcohols / Q000627:therapeutic use; D003911:Dextrans / Q000627:therapeutic use; D004231:Diuresis; D004620:Embolism, Fat / Q000097:blood / Q000150:complications / Q000628:therapy; D004976:Ethacrynic Acid / Q000627:therapeutic use; D005260:Female; D050723:Fractures, Bone / Q000150:complications*; D005665:Furosemide / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D000860:Hypoxia / Q000175:diagnosis; D008297:Male; D008875:Middle Aged; D009422:Nervous System Diseases / Q000517:prevention & control; D010100:Oxygen / Q000097:blood; D010102:Oxygen Inhalation Therapy; D011654:Pulmonary Edema / Q000517:prevention & control; D012131:Respiratory Insufficiency / Q000097:blood / Q000209:etiology / Q000628:therapy; D013256:Steroids / Q000627:therapeutic use; D014140:Tracheotomy; D014692:Ventilation-Perfusion Ratio
D000438:Alcohols; D003911:Dextrans; D013256:Steroids; D005665:Furosemide; D006493:Heparin; D004976:Ethacrynic Acid; D010100:Oxygen